Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 301–400 of 1,006
Rak, J., Filmus, J., & Kerbel, R. S. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00396-6 · Cited by 202
Metabolic Stress in Autophagy and Cell Death Pathways
Altman, B. J., & Rathmell, J. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008763 · Cited by 193
“HIF1a activitycan also antagonize p53-mediated apoptosis, especially with combined DNA damage (Graeber et al. 1996; Hao et al. 2008; Sendoel et al. 2010).”
BackgroundInterfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Ceramide Formation Leads to Caspase-3 Activation during Hypoxic PC12 Cell Death
Yoshimura, S.-I., Banno, Y., Nakashima, S., Takenaka, K., Sakai, H., Nishimura, Y., Sakai, N., Shimizu, S., Eguchi, Y., Tsujimoto, Y., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6921 · Cited by 203
Terphenyl-Based Bak BH3 α-Helical Proteomimetics as Low-Molecular-Weight Antagonists of Bcl-x L
Yin, H., Lee, G.-I., Sedey, K. A., Kutzki, O., Park, H. S., Orner, B. P., Ernst, J. T., Wang, H.-G., Sebti, S. M., & Hamilton, A. D. (2005) · Journal of the American Chemical Society · doi:10.1021/ja050122x · Cited by 198
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 199
“independent growth, and resistance to apoptosis despite increasing genetic instability.(52,53) Inhibition of VEGF reduces vessel size and”
BackgroundMankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Schubert, E. K., Tseng, J. R., Lawton, T. J., Linden, H. M., & Livingston, R. B. (2003) · PubMed · Cited by 200
Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., Murray, P. G., Perunovic, B., Anwar, M. S., Billingham, L., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603530 · Cited by 194
“…a micro-environmental factor related to poor response to radiation and chemotherapy, genetic instability, selection for resistance to apoptosis, and increased risk of invasion and metastasis (Brizel et al , 1996; Graeber et al , 1996; Hockel et al , 1996; Reynolds et al , 1996; Kim et al , 1997).”
Farnsworth, R. H., Lackmann, M., Achen, M. G., & Stacker, S. A. (2014) · Oncogene · doi:10.1038/onc.2013.304 · Cited by 193
Williams, A. C., Collard, T. J., & Paraskeva, C. (1999) · Oncogene · doi:10.1038/sj.onc.1202660 · Cited by 196
“Induction of wild type p53 function has also been observed in response to hypoxia (Graeber et al., 1996) and ribonucleotide depletion (Linke et al., 1996) suggesting a role for p53 as a `sensor' of cellular stress.”
BackgroundLife (and death) in a malignant tumour
Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/379019a0 · Cited by 198
Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 226
Elas, M., Williams, B. B., Parasca, A., Mailer, C., Pelizzari, C. A., Lewis, M. A., River, J. N., Karczmar, G. S., Barth, E. D., & Halpern, H. J. (2003) · Magnetic Resonance in Medicine · doi:10.1002/mrm.10408 · Cited by 194
“Lack of oxygen in a tissue (hypoxia) appears to predispose its surviving cells to mutagenesis, thereby increasing the likelihood that a malignant state will develop (3).”
BackgroundMolecular responses to hypoxia in tumor cells.
Kunz, M., & Ibrahim, S. M. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-23 · Cited by 224
“It could be shown that repeated exposure to low oxygen tension selected for p53 mutations and rendered tumor cells resistant to hypoxiainduced apoptosis [10].”
BackgroundStructural Adaptation and Heterogeneity of Normal and Tumor Microvascular Networks
Pries, A. R., Cornelissen, A. J. M., Sloot, A. A., Hinkeldey, M., Dreher, M. R., Höpfner, M., Dewhirst, M. W., & Secomb, T. W. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000394 · Cited by 192
“lost sensitivity to apoptosis [8] or that have a drug-resistant”
BackgroundHumphrey, J. S., Price, K., Gupta, E., Baxter, A., Bird, J., Sonnichsen, D., & Naglich, J. (2003) · Chemoradiation in Cancer Therapy · doi:10.1007/978-1-59259-325-5_21 · Cited by 193
Tanaka, T., Manome, Y., Wen, P., Kufe, D. W., & Fine, H. A. (1997) · Nature Medicine · doi:10.1038/nm0497-437 · Cited by 197
Graham, C. H., Forsdike, J., Fitzgerald, C. J., & Macdonald-Goodfellow, S. K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990209)80:4<595::aid-ijc18>3.0.co;2-b · Cited by 195
The Clinical Significance of Hypoxia in Human Cancers
Dhani, N., Fyles, A., Hedley, D., & Milosevic, M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.11.002 · Cited by 188
Acs, G., Zhang, P. J., McGrath, C. M., Acs, P., McBroom, J., Mohyeldin, A., Liu, S., Lu, H., & Verma, A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64314-3 · Cited by 193
“One insight into why low-oxygen conditions may affect the aggressiveness of cervical carcinomas is that in vitro hypoxia initiates the induction of apoptosis in HPV-infected, oncogenically transformed cells(114) and acts to select for populations of cells with reduced apoptotic sensitivity.(115) Kim and colleagues(114…”
BackgroundSignal transduction and transcription factors in rheumatic disease
Firestein, G. S., & Manning, A. M. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199904)42:4<609::aid-anr3>3.0.co;2-i · Cited by 198
A Molecular Genetic Model of Astrocytoma Histopathology
Louis, D. N. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb01062.x · Cited by 199
Hypoxia Inducible Factor Pathway and Physiological Adaptation: A Cell Survival Pathway?
Kumar, H., & Choi, D.-K. (2015) · Mediators of Inflammation · doi:10.1155/2015/584758 · Cited by 180
BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α
Chen, N., Chen, X., Huang, R., Zeng, H., Gong, J., Meng, W., Lu, Y., Zhao, F., Wang, L., & Zhou, Q. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805997200 · Cited by 190
Growth of Gold Nanoparticles in Human Cells
Anshup, Venkataraman, J. S., Subramaniam, C., Kumar, R. R., Priya, S., Kumar, T. R. S., Omkumar, R. V., John, A., & Pradeep, T. (2005) · Langmuir · doi:10.1021/la0519249 · Cited by 191
Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190
Target to apoptosis: A hopeful weapon for prostate cancer
Tang, D. G., & Porter, A. T. (1997) · The Prostate · doi:10.1002/(sici)1097-0045(19970901)32:4<229::aid-pros1>3.0.co;2-e · Cited by 191
Hypoxia-Inducible Factor-1α Mediates Hypoxia-Induced Delayed Neuronal Death That Involves p53
Halterman, M. W., Miller, C. C., & Federoff, H. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-16-06818.1999 · Cited by 159
“Conversely, human tumors harboring null or mutated p53 allele(s) exhibit reduced apoptosis under these conditions (Graeber et al., 1996; Levine, 1997; Carmeliet et al., 1998).”
BackgroundThe p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy
Bristow, R. G., Benchimol, S., & Hill, R. P. (1996) · Radiotherapy and Oncology · doi:10.1016/0167-8140(96)01806-3 · Cited by 192
Moreno-Sánchez, R., Marín-Hernández, A., Saavedra, E., Pardo, J. P., Ralph, S. J., & Rodríguez-Enríquez, S. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.025 · Cited by 184
In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis
Ganai, S., Arenas, R. B., Sauer, J. P., Bentley, B., & Forbes, N. S. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.10 · Cited by 186
Baek, J. H., Jang, J.-E., Kang, C.-M., Chung, H.-Y., Kim, N. D., & Kim, K.-W. (2000) · Oncogene · doi:10.1038/sj.onc.1203814 · Cited by 189
“Many reports demonstrate that tumor cells undergo adaptive processes, such as growth inhibition, genetic alterations, and angiogenesis in response to hypoxia or serum deprivation (Levy et al., 1995; Graeber et al., 1996).”
BackgroundSundfør, K., Lyng, H., & Rofstad, E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.586 · Cited by 186
Targeted genes and interacting proteins of hypoxia inducible factor-1.
Liu, W., Shen, S. M., Zhao, X., & Chen, G. Q. (2012) · Europe PMC (PubMed Central) · Cited by 249
Genetic evidence for a tumor suppressor role of HIF-2α
Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M. P., Herbert, J.-M., Burger, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.003 · Cited by 184
McClintock, D. S., Santore, M. T., Lee, V. Y., Brunelle, J., Budinger, G. R. S., Zong, W.-X., Thompson, C. B., Hay, N., & Chandel, N. S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.94-104.2002 · Cited by 184
“Oxygen deprivation has been shown to induce p53 protein accumulation and p53-dependent apoptosis in oncogenically transformed cells (8, 40).”
BackgroundTumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Hompland, T., Fjeldbo, C. S., & Lyng, H. (2021) · Cancers · doi:10.3390/cancers13030499 · Cited by 179
HIFs and tumors—causes and consequences
Höpfl, G., Ogunshola, O., & Gassmann, M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00538.2003 · Cited by 185
“The authors concluded that the loss of HIF-1 affects tumor growth by progressive selection of intensely proliferating cells, as occurs in the absence of p53 (78).”
BackgroundMethodLewis, J. S., Sharp, T. L., Laforest, R. A., Fujibayashi, Y., & Welch, M. J. (2001) · PubMed · Cited by 187
Multilineage embryonic hematopoiesis requires hypoxic ARNT activity
Adelman, D. M., Maltepe, E., & Simon, M. C. (1999) · Genes & Development · doi:10.1101/gad.13.19.2478 · Cited by 185
“Whereas the growth and division of many cell types is suppressed until O2 tensions return to normoxic levels (20% O2) (Graeber et al. 1996; Carmeliet et al. 1998), certain cell types must grow and proliferate in response to decreased O2.”
BackgroundA Multiple Scale Model for Tumor Growth
Alarcón, T., Byrne, H. M., & Maini, P. K. (2005) · Multiscale Modeling & Simulation · doi:10.1137/040603760 · Cited by 184
“It has been shown in several studies [64, 31, 65] that cells which have lost p53 expression (null cells) or have acquired a mutation in the p53 gene (mutant cells) can survive under hypoxia for longer periods than their wild-type counterparts due to the decrease in apoptosis caused by abnormal functioning of the p53 g…”
BackgroundAmeri, K., Lewis, C. E., Raida, M., Sowter, H., Hai, T., & Harris, A. L. (2004) · Blood · doi:10.1182/blood-2003-06-1859 · Cited by 177
Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Kim, Y., Lin, Q., Glazer, P., & Yun, Z. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167113 · Cited by 183
O’Donoghue, J. A., Zanzonico, P., Pugachev, A., Wen, B., Smith-Jones, P., Cai, S., Burnazi, E., Finn, R. D., Burgman, P., Ruan, S., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.057 · Cited by 184
Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L. G., Rani, R., Funel, N., Smid, K., Honeywell, R., Boggi, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.681 · Cited by 180
“Prolonged or recurrent tumour hypoxia selects for cancer cells with increased survival signalling and loss of apoptotic potential (Graeber et al, 1996).”
Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis.
Friedlander, R. M., Gagliardini, V, Rotello, R. J., & Yuan, J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.717 · Cited by 183
Telomere-related Genome Instability in Cancer
DE LANGE, T. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.032 · Cited by 182
Lyons, S. K., & Clarke, A. R. (1997) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a011630 · Cited by 182
Mutant p53 mediates survival of breast cancer cells
Lim, L. Y., Vidnovic, N., Ellisen, L. W., & Leong, C.-O. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605335 · Cited by 175
Strasser, A., Huang, D. C. S., & Vaux, D. L. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00019-x · Cited by 180
Swinson, D. E. B., Jones, J. L., Richardson, D., Cox, G., Edwards, J. G., & O'Byrne, K. J. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00172-1 · Cited by 183
“Persistent hypoxia mediates selection for mutant p53 as cells expressing wild type p53 undergo programmed cell death [26].”
BackgroundAQ4N: a new approach to hypoxia-activated cancer chemotherapy
Patterson, L. H., & McKeown, S. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1564 · Cited by 178
“In addition, absence of oxygen promotes a stress response which may favour development of a more malignant phenotype (Graeber et al, 1996).”
BackgroundMacleod, K. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00041-6 · Cited by 173
Angiogenesis modulation in cancer research: novel clinical approaches
Cristofanilli, M., Charnsangavej, C., & Hortobagyi, G. N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd819 · Cited by 179
“Low tumour oxygen levels have been associated with increased tumour growth and metastatic potentia”
BackgroundReceptor Tyrosine Kinase-Mediated Angiogenesis
Jeltsch, M., Leppanen, V.-M., Saharinen, P., & Alitalo, K. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009183 · Cited by 175
“Tumor vascularization correlates with hematogenous metastasis (Weidner et al. 1991; Graeber et al. 1996) and VEGF-A or VEGFR-2 have provided prognostic markers for metastasis in some studies (Bremnes et al. 2006).”
BackgroundThe Pervasive Presence of Fluctuating Oxygenation in Tumors
Cárdenas-Navia, L. I., Mace, D., Richardson, R. A., Wilson, D. F., Shan, S., & Dewhirst, M. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6387 · Cited by 176
Oxygen deprivation induced cell death: An update
Brunelle, J. K., & Chandel, N. S. (2002) · Apoptosis · doi:10.1023/a:1020668923852 · Cited by 171
Hypoxia as a target for combined modality treatments
Wouters, B. G., Weppler, S. A., Koritzinsky, M., Landuyt, W., Nuyts, S., Theys, J., Chiu, R. K., & Lambin, P. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00361-6 · Cited by 180
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Couse, J. F., Davis, V. L., Hanson, R. B., Jefferson, W. N., McLachlan, J. A., Bullock, B. C., Newbold, R. R., & Korach, K. S. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199708)19:4<236::aid-mc4>3.0.co;2-a · Cited by 76
Warde, P., O’Sullivan, B., Bristow, R. G., Panzarella, T., Keane, T. J., Gullane, P. J., Witterick, I. P., Payne, D., Liu, F.-F., McLean, M., et al. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00062-5 · Cited by 177
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W.-H., Wu, D.-H., Smaill, J. B., Patterson, A. V., & Ding, K. (2014) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10285 · Cited by 170
Heterogeneous expression of the lipocalin NGAL in primary breast cancers
Stoesz, S. P., Friedl, A., Haag, J. D., Lindstrom, M. J., Clark, G. M., & Gould, M. N. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981218)79:6<565::aid-ijc3>3.0.co;2-f · Cited by 155
Early Growth Response-1-dependent Apoptosis Is Mediated by p53
Nair, P., Muthukkumar, S., Sells, S. F., Han, S.-S., Sukhatme, V. P., & Rangnekar, V. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20131 · Cited by 176
Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 170
“Hypoxic cells are more resistant to both chemo and radiotherapy and have a more aggressive phenotype (Graeber et al, 1996; Bristow and Hill, 2008).”
BackgroundAssessment of tumour hypoxia for prediction of response to therapy and cancer prognosis
Jubb, A. M., Buffa, F. M., & Harris, A. L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00944.x · Cited by 175
POLYPLOID GIANT CELLS PROVIDE A SURVIVAL MECHANISM FOR p53 MUTANT CELLS AFTER DNA DAMAGE
Illidge, T. M., Cragg, M. S., Fringes, B., Olive, P., & Erenpreisa, J. A. (2000) · Cell Biology International · doi:10.1006/cbir.2000.0557 · Cited by 169
p53-Mediated Repression of Alpha-Fetoprotein Gene Expression by Specific DNA Binding
Lee, K. C., Crowe, A. J., & Barton, M. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1279 · Cited by 175
“One of the physiological responses of cells to reduced oxygen levels is the induction of p53 (26, 27).”
BackgroundThe origins of cancer robustness and evolvability
Tian, T., Olson, S., Whitacre, J. M., & Harding, A. (2011) · Integr. Biol. · doi:10.1039/c0ib00046a · Cited by 169
Bioreductive Drugs: from Concept to Clinic
McKeown, S. R., Cowen, R. L., & Williams, K. J. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.006 · Cited by 174
Chi, S.-W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4438 · Cited by 169
“, 1991, 1992), hypoxia (Graeber et al., 1996), mitotic spindle defects (Cross et al.”
BackgroundHMG-I/Y, a New c-Myc Target Gene and Potential Oncogene
Wood, L. J., Mukherjee, M., Dolde, C. E., Xu, Y., Maher, J. F., Bunton, T. E., Williams, J. B., & Resar, L. M. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5490-5502.2000 · Cited by 174
“Northern analysis. For Northern blot analysis, total RNA from the Myc-ER (19, 26, 27, 43 , 62) or MycD105-143-ER (19) cell line was isolated using the guanidinium-phenol-chloroform extraction method (Trizol; Gibco-BRL).”
MethodInfluentialNecrosis and Glioblastoma: A Friend or a Foe? A Review and a Hypothesis
Raza, S. M., Lang, F. F., Aggarwal, B. B., Fuller, G. N., Wildrick, D. M., & Sawaya, R. (2002) · Neurosurgery · doi:10.1097/00006123-200207000-00002 · Cited by 167
Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains.
Ossovskaya, V. S., Mazo, I. A., Chernov, M. V., Chernova, O. B., Strezoska, Z., Kondratov, R., Stark, G. R., Chumakov, P. M., & Gudkov, A. V. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10309 · Cited by 171
Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium.
Firestein, G. S., Nguyen, K., Aupperle, K. R., Yeo, M., Boyle, D. L., & Zvaifler, N. J. (1996) · Europe PMC (PubMed Central) · Cited by 190
Chapter 10 The Cancer Cell–Leukocyte Fusion Theory of Metastasis
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00410-7 · Cited by 166
Lin, Z., Mechalakos, J., Nehmeh, S., Schoder, H., Lee, N., Humm, J., & Ling, C. C. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.050 · Cited by 170
Hypoxia in head and neck cancer: How much, how important?
Janssen, H. L., Haustermans, K. M., Balm, A. J., & Begg, A. C. (2005) · Head & Neck · doi:10.1002/hed.20223 · Cited by 169
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169
“The subsequent recognition that a number of genes, including growth factors, oncogenes, transcriptional factors, and glycolytic enzymes, can bemodulated by hypoxia (Giaccia, 1996; Graeber et al., 1996) formed the basis of many current molecular targeting strategies seeking to take advantage of the tumor microenvironme…”
Span, P. N., & Bussink, J. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.002 · Cited by 163
Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours
Toffoli, S., & Michiels, C. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06454.x · Cited by 169
Fluctuating and Diffusion-Limited Hypoxia in Hypoxia-Induced Metastasis
Rofstad, E. K., Galappathi, K., Mathiesen, B., & Ruud, E.-B. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1967 · Cited by 171
Redox regulation of p53 during hypoxia
Chandel, N. S., Vander Heiden, M. G., Thompson, C. B., & Schumacker, P. T. (2000) · Oncogene · doi:10.1038/sj.onc.1203727 · Cited by 167
“Hypoxia-induced cell death may function as an important safeguard against tumor development (Graeber et al., 1996; Kinzler and Vogelstein, 1996).”
BackgroundInfluentialMay, D., Itin, A., Gal, O., Kalinski, H., Feinstein, E., & Keshet, E. (2005) · Oncogene · doi:10.1038/sj.onc.1208325 · Cited by 167
“Since hypoxia is known to be a major selection force in p53-deficient (Graeber et al., 1996), ability to upregulate Ero1-La in hypoxic microenvironments of these tumors is physiologically relevant.”
Background(2003) · PubMed · Cited by 167
Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer
Kim, S. J., Rabbani, Z. N., Dewhirst, M. W., Vujaskovic, Z., Vollmer, R. T., Schreiber, E.-G., Oosterwijk, E., & Kelley, M. J. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.036 · Cited by 165
“Tumor hypoxia has been reported to trigger tumor cells to undergo genetic alteration and adaptive changes that allow them to survive and proliferate [2,3].”
Momand, J., & Zambetti, G. P. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3<343::aid-jcb1>3.0.co;2-v · Cited by 168
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Li, J. N., Gorospe, M., Chrest, F. J., Kumaravel, T. S., Evans, M. K., Han, W. F., & Pizer, E. S. (2001) · PubMed · Cited by 166
The anaemia of cancer: death by a thousand cuts
Spivak, J. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1648 · Cited by 161
“, and in part due to the hypoxia-mediated selection of p53-resistant tumour cell”
BackgroundMurphy, B. J., Andrews, G. K., Bittel, D. C., Discher, D. J., McCue, J. M., Green, C. J., Yanovsky, M., Giaccia, A. J., Sutherland, R. M., Laderoute, K. R., et al. (1999) · PubMed · Cited by 185
Self-citationModulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species
Vieira, H. L. A., Alves, P. M., & Vercelli, A. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.01.007 · Cited by 164
“Hypoxia may provide a strong selective pressure capable of regulating tumor growth and eventually allowing the most aggressive malignant cells to survive (Graeber et al., 1996; Harris, 2002; Semenza, 2000b).”
BackgroundMolecular mechanisms of hypoxia in cancer
Challapalli, A., Carroll, L., & Aboagye, E. O. (2017) · Clinical and Translational Imaging · doi:10.1007/s40336-017-0231-1 · Cited by 163
“Metabolic changes [36, 37] Hypoxia causes tumour cells to switch to glycolysis for energy production (due to decrease in mitochondrial oxidation)”
BackgroundGottlieb, E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1381 · Cited by 166
“These signals, including hypoxia (Graeber et al., 1996) and mice harbor the p53-dependent promoter of the mdm2 ribonucleotide depletion (Linke et al., 1996), can alsogene, fused to a lacZ reporter gene.”
BackgroundWilliams, S. A., Pettaway, C. A., Song, R., Papandreou, C. N., Logothetis, C. J., & McConkey, D. J. (2003) · PubMed · Cited by 164
Milosevic, M., Fyles, A., Hedley, D., & Hill, R. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.006 · Cited by 163
Redox signalling and transition metals in the control of the p53 pathway
Méplan, C., Richard, M.-J., & Hainaut, P. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00297-x · Cited by 166
Chromosome 18q allelic loss and prognosis in stage II and III colon cancer
Lanza, G., Matteuzzi, M., Gafá, R., Orvieto, E., Maestri, I., Santini, A., & del Senno, L. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980821)79:4<390::aid-ijc14>3.0.co;2-9 · Cited by 141
p53 Expression Induces Apoptosis in Hippocampal Pyramidal Neuron Cultures
Jordán, J., Galindo, M. F., Prehn, J. H. M., Weichselbaum, R. R., Beckett, M., Ghadge, G. D., Roos, R. P., Leiden, J. M., & Miller, R. J. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01397.1997 · Cited by 167
“These include ischemia (Chopp et al., 1992; Li et al., 1994), seizure activity (Sakhi et al., 1994; Morrison et al., 1996) and the death of dentate granule cells after adrenalectomy (Schreiber et al., 1994). p53 is also induced in replicating cells after hypoxia (Graeber et al., 1995, 1996).”
BackgroundLouie, E., Nik, S., Chen, J.-S., Schmidt, M., Song, B., Pacson, C., Chen, X. F., Park, S., Ju, J., & Chen, E. I. (2010) · Breast Cancer Research · doi:10.1186/bcr2773 · Cited by 156
“It has been postulated that hypoxia contributes directly to the development of more aggressive cancers by exerting selective pressure on the tumor cell population to favor cells that can survive decreased O2 and nutrients [18-20].”
Background
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.